The proinflammatory cytokine high-mobility group box-1 mediates retinal neuropathy induced by diabetes

Mediators of Inflammation

Volumn 2014, Issue , 2014, Pages

  Abu El Asrar, Ahmed M ^a,b   Mairaj Siddiquei, Mohammad ^a   Nawaz, Mohd Imtiaz ^a   Geboes, Karel ^c   Mohammad, Ghulam ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING ABDUL AZIZ UNIVERSITY HOSPITAL   (Saudi Arabia)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; GLUTAMATE AMMONIA LIGASE; GLUTAMIC ACID; GLYCYRRHIZIC ACID; GLYOXALASE; GLYOXALASE 1; HIGH MOBILITY GROUP B1 PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SYNAPTOPHYSIN; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; CYTOKINE; HBP1 PROTEIN, RAT; LACTOYLGLUTATHIONE LYASE; SYP PROTEIN, RAT;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DIABETIC RETINAL NEUROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DOWN REGULATION; ENZYME ACTIVATION; EPIRETINAL MEMBRANE; MALE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; VITREOUS BODY; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; IMMUNOLOGY; INFLAMMATION; METABOLISM; RETINA; SPRAGUE DAWLEY RAT;

ANIMALS; CYTOKINES; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; GLUTAMATE-AMMONIA LIGASE; GLYCYRRHIZIC ACID; HMGB1 PROTEIN; INFLAMMATION; LACTOYLGLUTATHIONE LYASE; MALE; RATS; RATS, SPRAGUE-DAWLEY; RETINA; SYNAPTOPHYSIN; TYROSINE 3-MONOOXYGENASE;

EID: 84897491156     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2014/746415     Document Type: Article

References (51)

1. Seki M., Tanaka T., Nawa H., Usui T., Fukuchi T., Ikeda K., Abe H., Takei N., Involvement of brain-derived neurotrophic factor in early retinal neuropathy of streptozotocin-induced diabetes in rats: therapeutic potential of brain-derived neurotrophic factor for dopaminergic amacrine cells. Diabetes 2004 53 9 2412 2419 2-s2.0-4344599833 10.2337/diabetes.53.9.2412 (Pubitemid 39145597)
2. Barber A. J., A new view of diabetic retinopathy: a neurodegenerative disease of the eye. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2003 27 2 283 290 2-s2.0-0037376768 10.1016/S0278-5846(03)00023-X (Pubitemid 36351495)
3. Sasaki M., Ozawa Y., Kurihara T., Kubota S., Yuki K., Noda K., Kobayashi S., Ishida S., Tsubota K., Neurodegenerative influence of oxidative stress in the retina of a murine model of diabetes. Diabetologia 2010 53 5 971 979 2-s2.0-77952089530 10.1007/s00125-009-1655-6
4. Abu El-Asrar A. M., Dralands L., Missotten L., Al-Jadaan I. A., Geboes K., Expression of apoptosis markers in the retinas of human subjects with diabetes. Investigative Ophthalmology and Visual Science 2004 45 8 2760 2766 2-s2.0-3242884227 10.1167/iovs.03-1392 (Pubitemid 38998875)
5. Van Beijnum J. R., Buurman W. A., Griffioen A. W., Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis 2008 11 1 91 99 2-s2.0-41049117932 10.1007/s10456-008-9093-5
6. Treutiger C. J., Mullins G. E., Johansson A.-S. M., Rouhiainen A., Rauvala H. M. E., Erlandsson-Harris H., Andersson U., Yang H., Tracey K. J., Andersson J., Palmblad J. E. W., High mobility group 1 B-box mediates activation of human endothelium. Journal of Internal Medicine 2003 254 4 375 385 2-s2.0-0141750710 10.1046/j.1365-2796.2003.01204.x (Pubitemid 37211261)
7. Fiuza C., Bustin M., Talwar S., Tropea M., Gerstenberger E., Shelhamer J. H., Suffredini A. F., Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003 101 7 2652 2660 2-s2.0-0037769813 10.1182/blood-2002-05-1300 (Pubitemid 36857626)
8. Luan Z.-G., Zhang H., Yang P.-T., Ma X.-C., Zhang C., Guo R.-X., HMGB1 activates nuclear factor- B signaling by RAGE and increases the production of TNF- α in human umbilical vein endothelial cells. Immunobiology 2010 215 12 956 962 2-s2.0-78049291345 10.1016/j.imbio.2009.11.001
9. Takeuchi M., Takino J.-I., Yamagishi S.-I., Involvement of the toxic AGEs (TAGE)-RAGE system in the pathogenesis of diabetic vascular complications: a novel therapeutic strategy. Current Drug Targets 2010 11 11 1468 1482 2-s2.0-79954991400
10. Tang D., Kang R., Zeh H. J. 3rd, Lotze M. T., High-mobility group box 1, oxidative stress, and disease. Antioxidants and Redox Signaling 2011 14 7 1315 1335 2-s2.0-79952366675 10.1089/ars.2010.3356
11. Joussen A. M., Poulaki V., Le M. L., Koizumi K., Esser C., Janicki H., Schraermeyer U., Kociok N., Fauser S., Kirchhof B., Kern T. S., Adamis A. P., A central role for inflammation in the pathogenesis of diabetic retinopathy. The FASEB Journal 2004 18 12 1450 1452 2-s2.0-7044228789 10.1096/fj.03-1476fje (Pubitemid 39561611)
12. Miyamoto K., Khosrof S., Bursell S.-E., Rohan R., Murata T., Clermont A. C., Aiello L. P., Ogura Y., Adamis A. P., Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proceedings of the National Academy of Sciences of the United States of America 1999 96 19 10836 10841 2-s2.0-0032863021 10.1073/pnas.96.19.10836 (Pubitemid 29442230)
13. Gao H.-M., Zhou H., Zhang F., Wilson B. C., Kam W., Hong J.-S., HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration. Journal of Neuroscience 2011 31 3 1081 1092 2-s2.0-78751502344 10.1523/JNEUROSCI.3732-10.2011
14. Kim J.-B., Joon S. C., Yu Y.-M., Nam K., Piao C.-S., Kim S.-W., Lee M.-H., Han P.-L., Park J.-S., Lee J.-K., HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain. Journal of Neuroscience 2006 26 24 6413 6421 2-s2.0-33745788420 10.1523/JNEUROSCI.3815-05.2006 (Pubitemid 44318322)
15. Qiu J., Nishimura M., Wang Y., Sims J. R., Qiu S., Savitz S. I., Salomone S., Moskowitz M. A., Early release of HMGB-1 from neurons after the onset of brain ischemia. Journal of Cerebral Blood Flow and Metabolism 2008 28 5 927 938 2-s2.0-42549139329 10.1038/sj.jcbfm.9600582 (Pubitemid 351589627)
16. Kim S.-W., Lim C.-M., Kim J.-B., Shin J.-H., Lee S., Lee M., Lee J.-K., Extracellular HMGB1 released by NMDA treatment confers neuronal apoptosis via RAGE-p38 MAPK/ERK signaling pathway. Neurotoxicity Research 2011 20 2 159 169 2-s2.0-80052615268 10.1007/s12640-010-9231-x
17. Faraco G., Fossati S., Bianchi M. E., Patrone M., Pedrazzi M., Sparatore B., Moroni F., Chiarugi A., High mobility group box 1 protein is released by neural cells upon different stresses and worsens ischemic neurodegeneration in vitro and in vivo. Journal of Neurochemistry 2007 103 2 590 603 2-s2.0-34848917621 10.1111/j.1471-4159.2007.04788.x (Pubitemid 47498027)
18. Liu K., Mori S., Takahashi H. K., Tomono Y., Wake H., Kanke T., Sato Y., Hiraga N., Adachi N., Yoshino T., Nishibori M., Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats. The FASEB Journal 2007 21 14 3904 3916 2-s2.0-36849076615 10.1096/fj.07-8770com (Pubitemid 350232348)
19. Pedrazzi M., Raiteri L., Bonanno G., Patrone M., Ledda S., Passalacqua M., Milanese M., Melloni E., Raiteri M., Pontremoli S., Sparatore B., Stimulation of excitatory amino acid release from adult mouse brain glia subcellular particles by high mobility group box 1 protein. Journal of Neurochemistry 2006 99 3 827 838 2-s2.0-33750078962 10.1111/j.1471-4159.2006. 04120.x (Pubitemid 44583442)
20. El-Asrar A. M. A., Missotten L., Geboes K., Expression of high-mobility groups box-1/receptor for advanced glycation end products/osteopontin/early growth response-1 pathway in proliferative vitreoretinal epiretinal membranes. Molecular Vision 2011 17 508 518 2-s2.0-79952145525
21. El-Asrar A. M. A., Nawaz M. I., Kangave D., Geboes K., Ola M. S., Ahmad S., Al-Shabrawey M., High-mobility group box-1 and biomarkers of inflammation in the vitreous from patients with proliferative diabetic retinopathy. Molecular Vision 2011 17 1829 1838 2-s2.0-79960729070
22. Abu El-Asrar A. M., Nawaz M. I., Kangave D., Siddiquei M. M., Geboes K., Osteopontin and other regulators of angiogenesis and fibrogenesis in the vitreous from patients with proliferative vitreoretinal disorders. Mediators of Inflammation 2012 2012 8 10.1155/2012/493043 493043
23. Mohammad G., Siddiquei M. M., Othman A., Al-Shabrawey M., Abu El-Asrar A. M., High-mobility group box-1 protein activates inflammatory signaling pathway components and disrupts retinal vascular-barrier in the diabetic retina. Experimental Eye Research 2013 107 101 109
24. Mollica L., De Marchis F., Spitaleri A., Dallacosta C., Pennacchini D., Zamai M., Agresti A., Trisciuoglio L., Musco G., Bianchi M. E., Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chemistry and Biology 2007 14 4 431 441 2-s2.0-34247181253 10.1016/j.chembiol. 2007.03.007 (Pubitemid 46617319)
25. Gastinger M. J., Singh R. S. J., Barber A. J., Loss of cholinergic and dopaminergic amacrine cells in streptozotocin-diabetic rat and Ins2Akita-diabetic mouse retinas. Investigative Ophthalmology and Visual Science 2006 47 7 3143 3150 2-s2.0-33746729952 10.1167/iovs.05-1376 (Pubitemid 351639794)
26. Feit-Leichman R. A., Kinouchi R., Takeda M., Fan Z., Mohr S., Kern T. S., Chen D. F., Vascular damage in a mouse model of diabetic retinopathy: relation to neuronal and glial changes. Investigative Ophthalmology and Visual Science 2005 46 11 4281 4287 2-s2.0-33644689817 10.1167/iovs.04-1361 (Pubitemid 44264633)
27. Spiwoks-Becker I., Vollrath L., Seeliger M. W., Jaissle G., Eshkind L. G., Leube R. E., Synaptic vesicle alterations in rod photoreceptors of synaptophysin-deficient mice. Neuroscience 2001 107 1 127 142 2-s2.0-0035834813 10.1016/S0306-4522(01)00345-1 (Pubitemid 34020691)
28. Vanguilder H. D., Brucklacher R. M., Patel K., Ellis R. W., Freeman W. M., Barber A. J., Diabetes downregulates presynaptic proteins and reduces basal synapsin i phosphorylation in rat retina. European Journal of Neuroscience 2008 28 1 1 11 2-s2.0-54049107380 10.1111/j.1460-9568.2008.06322.x
29. Kurihara T., Ozawa Y., Nagai N., Shinoda K., Noda K., Imamura Y., Tsubota K., Okano H., Oike Y., Ishida S., Angiotensin II type 1 receptor signaling contributes to synaptophysin degradation and neuronal dysfunction in the diabetic retina. Diabetes 2008 57 8 2191 2198 2-s2.0-50949116171 10.2337/db07-1281
30. Ozawa Y., Kurihara T., Sasaki M., Ban N., Yuki K., Kubota S., Tsubota K., Neural degeneration in the retina of the streptozotocin-induced type 1 diabetes model. Experimental Diabetes Research 2011 2011 7 2-s2.0-84855582942 10.1155/2011/108328 108328
31. Szabadfi K., Atlasz T., Kiss P., Reglodi D., Szabo A., Kovacs K., Szalontai B., Setalo G. Jr., Banki E., Csanaky K., Tamas A., Gabriel R., Protective effects of the neuropeptide PACAP in diabetic retinopathy. Cell and Tissue Research 2012 348 1 37 46 2-s2.0-84859444917 10.1007/s00441-012-1349-0
32. Wan C., Liu N. N., Liu L. M., Cai N., Chen L., Effect of adenovirus-mediated brain derived neurotrophic factor in early retinal neuropathy of diabetes in rats. International Journal of Ophthalmology 2010 3 145 148
33. Northington F. K., Hamill R. W., Banerjee S. P., Dopamine-stimulated adenylate cyclase and tyrosine hydroxylase in diabetic rat retina. Brain Research 1985 337 1 151 154 2-s2.0-0021824389 10.1016/0006-8993(85)91621-X (Pubitemid 15008296)
34. Lieth E., LaNoue K. F., Antonetti D. A., Ratz M., Diabetes reduces glutamate oxidation and glutamine synthesis in the retina. Experimental Eye Research 2000 70 6 723 730 2-s2.0-0033843835 10.1006/exer.2000.0840
35. Xu-hui Y., Hong Z., Yu-hong W., Li-juan L., Yan T., Ping L., Time-dependent reduction of glutamine synthetase in retina of diabetic rats. Experimental Eye Research 2009 89 6 967 971 2-s2.0-70350732811 10.1016/j.exer.2009.08.006
36. Lieth E., Barber A. J., Xu B., Dice C., Ratz M. J., Tanase D., Strother J. M., Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy. Penn State Retina Research Group. Diabetes 1998 47 815 820 (Pubitemid 28201813)
37. Kowluru R. A., Engerman R. L., Case G. L., Kern T. S., Retinal glutamate in diabetes and effect of antioxidants. Neurochemistry International 2001 38 5 385 390 2-s2.0-0035104682 10.1016/S0197-0186(00)00112-1 (Pubitemid 32166895)
38. Lecleire-Collet A., Tessier L. H., Massin P., Forster V., Brasseur G., Sahel J. A., Picaud S., Advanced glycation end products can induce glial reaction and neuronal degeneration in retinal explants. British Journal of Ophthalmology 2005 89 12 1631 1633 2-s2.0-28444466991 10.1136/bjo.2005.079491 (Pubitemid 41729910)
39. Glenn J. V., Stitt A. W., The role of advanced glycation end products in retinal ageing and disease. Biochimica et Biophysica Acta 2009 1790 10 1109 1116 2-s2.0-69949085013 10.1016/j.bbagen.2009.04.016
40. Karachalias N., Babaei-Jadidi R., Ahmed N., Thornalley P. J., Accumulation of fructosyl-lysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic rats. Biochemical Society Transactions 2003 31 6 1423 1425 2-s2.0-0348049805 (Pubitemid 38030991)
41. Shinohara M., Thornalley P. J., Giardino I., Beisswenger P., Thorpe S. R., Onorato J., Brownlee M., Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. Journal of Clinical Investigation 1998 101 5 1142 1147 2-s2.0-0032032578 (Pubitemid 28125293)
42. Miller A. G., Tan G., Binger K. J., Pickering R. J., Thomas M. C., Nagaraj R. H., Cooper M. E., Wilkinson-Berka J. L., Candesartan attenuates diabetic retinal vascular pathology by restoring glyoxalase-I function. Diabetes 2010 59 12 3208 3215 2-s2.0-78650044928 10.2337/db10-0552
43. Berner A. K., Brouwers O., Pringle R., Klaassen I., Colhoun L., McVicar C., Brockbank S., Curry J. W., Miyata T., Brownlee M., Schlingemann R. O., Schalkwijk C., Stitt A. W., Protection against methylglyoxal-derived AGEs by regulation of glyoxalase 1 prevents retinal neuroglial and vasodegenerative pathology. Diabetologia 2012 55 3 845 854 2-s2.0-84856729229 10.1007/s00125-011-2393-0
44. Kawahara K.-I., Biswas K. K., Unoshima M., Ito T., Kikuchi K., Morimoto Y., Iwata M., Tancharoen S., Oyama Y., Takenouchi K., Nawa Y., Arimura N., Jie M. X., Shrestha B., Miura N., Shimizu T., Mera K., Arimura S.-I., Taniguchi N., Iwasaka H., Takao S., Hashiguchi T., Maruyama I., C-reactive protein induces high-mobility group box-1 protein release through activation of p38MAPK in macrophage RAW264.7 cells. Cardiovascular Pathology 2008 17 3 129 138 2-s2.0-42949085762 10.1016/j.carpath.2007.08.006 (Pubitemid 351615295)
45. Willenbrock S., Braun O., Baumgart J., Lange S., Junghanss C., Heisterkamp A., Nolte I., Bullerdiek J., Murua Escobar H., TNF- α induced secretion of HMGB1 from non-immune canine mammary epithelial cells (MTH53A). Cytokine 2012 57 2 210 220 2-s2.0-84855463690 10.1016/j.cyto.2011.11.011
46. Hayakawa K., Arai K., Lo E. H., Role of ERK MAP kinase and CRM1 in IL-1 β -stimulated release of HMGB1 from cortical astrocytes. GLIA 2010 58 8 1007 1015 2-s2.0-77952576789 10.1002/glia.20982
47. Kim S.-W., Jin Y., Shin J.-H., Kim I.-D., Lee H.-K., Park S., Han P.-L., Lee J.-K., Glycyrrhizic acid affords robust neuroprotection in the postischemic brain via anti-inflammatory effect by inhibiting HMGB1 phosphorylation and secretion. Neurobiology of Disease 2012 46 1 147 156 2-s2.0-84858149685 10.1016/j.nbd.2011.12.056
48. Ohnishi M., Katsuki H., Fukutomi C., Takahashi M., Motomura M., Fukunaga M., Matsuoka Y., Isohama Y., Izumi Y., Kume T., Inoue A., Akaike A., HMGB1 inhibitor glycyrrhizin attenuates intracerebral hemorrhage-induced injury in rats. Neuropharmacology 2011 61 5-6 975 980 2-s2.0-80051793826 10.1016/j.neuropharm.2011.06.026
49. Gong G., Yuan L.-B., Hu L., Wu W., Yin L., Hou J.-L., Liu Y.-H., Zhou L.-S., Glycyrrhizin attenuates rat ischemic spinal cord injury by suppressing inflammatory cytokines and HMGB1. Acta Pharmacologica Sinica 2012 33 1 11 18 2-s2.0-84855471701 10.1038/aps.2011.151
50. Stormer F. C., Reistad R., Alexander J., Glycyrrhizic acid in liquorice-evaluation of health hazard. Food and Chemical Toxicology 1993 31 4 303 312 2-s2.0-0027538613 10.1016/0278-6915(93)90080-I (Pubitemid 23122371)
51. Celik M. M., Karakus A., Zeren C., Demir M., Bayarogullari H., Duru M., Al M., Licorice induced hypokalemia, edema, and thrombocytopenia. Human & Experimental Toxicology 2012 31 1295 1298